Tesofensine

The downside is dominated by the safety dimension, full stop. Tesofensine's cardiovascular signal is the single biggest reason its development stalled and the single biggest reason it sits in caution despite strong efficacy. Around that, the side-effect load is real, reversibility is weak because weight regains on stopping, and there is a genuine opportunity cost because an approved GLP-1 is the better-evidenced alternative for most people. Cost is moderate given no insured supply, effort is low since it is a once-daily pill, and dependency is a nuanced but real stimulant-class concern.

There is also a downside that sits outside the molecule itself but lands on anyone who would use it. Because there is no FDA or EMA approval, there is no regulated, quality-controlled supply in most of the world. In practice that means grey-market research chemical or compounded material of uncertain purity, uncertain dose accuracy, and no oversight on what is really in the vial. That sourcing problem is extrinsic to the pharmacology, so it does not change the safety score for the drug as studied, but it is a real-world hazard layered on top of the intrinsic cardiovascular risk. For a drug whose safe use depends on careful dose titration and tight cardiovascular monitoring, starting from material you cannot trust is the worst possible footing.

Safety Risk (4.0/5.0): Safety risk is high, and it is set by chronic cardiovascular strain rather than acute toxicity. The defining liability is sympathetic activation: heart rate rose about 7.4 beats per minute at 0.5 mg in the pivotal trial, per Astrup 2008, Lancet, and up to about 6.8 beats per minute in the neuro meta-analysis, per Astrup 2008, Obesity. Even where blood pressure did not rise much at the lower doses, a sustained tachycardia in people already at elevated cardiometabolic risk is exactly the signal obesity-drug regulators treat as disqualifying, especially in the shadow of the sibutramine withdrawal, another monoamine reuptake inhibitor pulled for cardiovascular events. That is why development stalled, and why the follow-up Tesomet product deliberately added the beta-blocker metoprolol to neutralize the heart-rate signal, which it did, per Huynh 2022. When the fix is to add a heart drug, the heart effect is the core problem. This score does not go lower only because the signal is a chronic risk rather than an acute, immediate danger at standard doses.

Side Effect Profile (3.3/5.0): Side effects are frequent and stimulant-flavored. The common complaints in the pivotal trial were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia, per Astrup 2008, Lancet. Even in the metoprolol-buffered Tesomet trial, sleep disturbance ran about 50 percent versus 13 percent on placebo, dry mouth 43 percent versus zero, and headache 36 percent versus zero, with the one serious adverse event being exacerbated anxiety leading to discontinuation, per Huynh 2022. Dry mouth and insomnia are the most consistent. These are mostly tolerability problems rather than dangers, but they are common enough to matter day to day.

Financial Cost (3.0/5.0): Cost is moderate and unreliable rather than simply high. There is no FDA-approved, insured product, so in the US there is no covered supply at all. It is marketed in a few Latin American markets, and elsewhere it circulates as grey-market or compounded material of uncertain price and quality. The per-dose cost is not extreme, but the absence of a reliable, regulated supply chain is the real cost story here. On top of the material itself, safe use would require regular clinician visits, baseline and ongoing cardiovascular monitoring, and the blood-pressure and heart-rate tracking that the mechanism demands, none of which is free. So the honest total cost is the drug plus the medical oversight it needs, and for most people that combined spend would buy a far better-evidenced GLP-1 instead, which is why the cost score lands in the middle rather than looking cheap on a per-tablet basis.

Time/Effort Burden (2.2/5.0): Effort is low for the act of taking it, which is what this dimension measures. Tesofensine is a once-daily oral tablet, with the main practical wrinkle being that it is best dosed early in the day to limit insomnia. There is no injection, no reconstitution, and no cold-chain storage, so the mechanical routine is about as simple as a daily medicine gets. Compared with the injectable peptides in this space, the daily pill is far easier to live with. The real work sits in the monitoring rather than the dosing: checking resting heart rate and blood pressure, watching sleep and mood, and staying in touch with a clinician. That ongoing vigilance is genuine effort, but it is supervision effort rather than administration effort, which is why the burden score stays on the lower side even though the drug demands attention.

Opportunity Cost (3.2/5.0): Opportunity cost is genuine and higher than for most weight interventions, because a clearly better option exists. An approved GLP-1 such as semaglutide or tirzepatide delivers comparable or larger weight loss with a cleaner cardiovascular profile, Phase 3 evidence, and FDA approval, without the sympathetic-activation and stimulant-class liabilities. For almost anyone considering tesofensine for routine obesity, the time, money, and risk would be better spent on a GLP-1 and the diet, training, and sleep basics that move the same goal with far more certainty.

Dependency/Withdrawal (3.0/5.0): Dependency is a nuanced but real concern. A triple monoamine, especially dopamine, reuptake inhibitor is in the same neurochemical family as stimulants with abuse potential, which is exactly why regulators were wary, per Coulter 2018. The one dedicated human abuse-liability study is reassuring: tesofensine did not differ from placebo on subjective measures and was lower than amphetamine, with potential judged no greater than bupropion or atomoxetine, per Schoedel 2010. That tempers the concern but does not erase it, because chronic dopaminergic tone still raises functional-dependence and rebound questions, and the appetite control fades when the drug stops.

Reversibility (2.2/5.0): Reversibility is weak, driven mainly by weight regain. As an appetite suppressant, the weight benefit reverses once you stop and hunger returns, per Coulter 2018, and the long-term mood and adaptation effects of chronically modulating three monoamines were never resolved in humans because the program stalled before long trials. The drug itself clears over time and the acute pharmacology is not permanent, but the practical reality is that the result you paid for, the weight loss, does not stick. Expect to regain off-drug.